Introduction
GLP-1 drugs such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are primarily prescribed to manage type 2 diabetes. However, recent studies suggest they could also play a crucial role in reducing serious infections, including tuberculosis (TB). In this article, we explore these findings and understand how these medications could revolutionize our approach to infectious diseases.
GLP-1: An Overview
GLP-1s (glucagon-like peptide 1) are a class of drugs that mimic a natural hormone, GLP-1, known for stimulating insulin and controlling blood sugar. Since their introduction, these medications have proven effective in treating type 2 diabetes, reducing HbA1c levels, and aiding in weight loss for some patients.
Discovery of Anti-Infective Potential
Two recent studies have highlighted a potentially beneficial side effect of GLP-1s: a reduction in the risk of serious infections. Published in Nature Communications, the first study revealed that individuals using GLP-1s were significantly less likely to develop tuberculosis. Tuberculosis remains one of the world’s most deadly infections, causing approximately 1.2 million deaths in 2024. Researchers used a large database of medical records to compare health outcomes of GLP-1 users to those taking other antidiabetic drugs between 2017 and 2025.
Observed Protective Effect
The second study, published in the BMJ, focused on tirzepatide and its impact on cardiovascular health in patients with type 2 diabetes. Unexpectedly, the study showed that tirzepatide users had a reduced risk of infections requiring hospitalization. Moreover, these patients had lower overall mortality, including mortality from infections.
Possible Mechanisms
While the exact mechanisms by which GLP-1s reduce the risk of serious infections are not fully understood, several hypotheses have been proposed. One is the enhancement of the immune response. GLP-1s might boost the function of macrophages, key cells in defense against bacterial infections. Another hypothesis is their anti-inflammatory effect, reducing systemic inflammation that can make the body more vulnerable to infections.
Implications for Vulnerable Patients
People with type 2 diabetes are often at higher risk for infections due to high blood glucose and associated complications. If GLP-1s can reduce this risk, it could transform their healthcare management, decreasing hospitalizations and improving quality of life.
Conclusion
The recent findings on GLP-1s open new perspectives in the treatment of serious infections. Although additional research is needed to confirm these results, the potential is undeniable. For patients and healthcare professionals alike, these drugs could become a valuable weapon in combating infections.
Let's discuss your project in 15 minutes.